Diagnostic performance of Des-γ-carboxy prothrombin (DCP) for Hepatocellular carcinoma: A Bivariate Meta-analysis

Neoplasma

Volumn 59, Issue 2, 2012, Pages 150-159

  Gao, P ^a   Li, M ^a   Tian, Q B ^a   Liu, D W ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Des carboxy prothrombin; Diagnostic test; Hepatocellular carcinoma; Pooled analysis; Sandwich ELISA

Indexed keywords

DECARBOXYPROTHROMBIN; BIOLOGICAL MARKER; PROTEIN PRECURSOR; PROTHROMBIN; TUMOR MARKER;

AREA UNDER THE CURVE; ARTICLE; BIVARIATE ANALYSIS; CHRONIC HEPATITIS; DIAGNOSTIC ACCURACY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC HETEROGENEITY; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; META ANALYSIS; NOMOGRAM; PERFORMANCE; PUBLISHING; QUALITY CONTROL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; BLOOD; LIVER TUMOR; PROGNOSIS;

BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; PROGNOSIS; PROTEIN PRECURSORS; PROTHROMBIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84863856216     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2012_020     Document Type: Article

References (45)

1. BOSCH FX, RIBES J, DIAZ M, CLERIES R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127: S5-S16. http://dx.doi.org/10.1053/j.gastro.2004.09.011
2. PARKIN DM, BRAY F, FERLAY J, PISANI P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153-156. http://dx.doi.org/10.1002/ijc.1440
3. FARMER DG, ROSOVE MH, SHAKED A, BUSUTTIL RW. Current treatment modalities for hepatocellular carcinoma. Ann Surg 1994; 219: 236-247.
4. BRUIX J, SHERMAN M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236. http://dx.doi. org/10.1002/hep.20933
5. LLOVET JM, SCHWARTZ M, MAZZAFERRO V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005; 25: 181-200.
6. LIAW YF, TAI DI, CHU CM, LIN DY, SHEEN IS et al. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study. Gastroenterology 1986; 90: 263-267.
7. ZHANG BH, YANG BH, TANG ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130: 417-422.
8. FRANCA AV, ELIAS JUNIOR J, LIMA BL, MARTINELLI AL, CARRILHO FJ. Diagnosis, staging and treatment of hepatocellular carcinoma. Braz J Med Biol Res 2004; 37: 1689-1705.
9. TONG MJ, BLATT LM, KAO VW. Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America. J Gastroenterol Hepatol 2001; 16: 553-559. http://dx.doi.org/10.1046/j.1440-1746.2001.02470.x
10. CHEN DS, SUNG JL, SHEU JC, LAI MY, HOW SW et al. Serum alpha-fetoprotein in the early stage of human hepatocellular carcinoma. Gastroenterology 1984; 86: 1404-1409.
11. DI BISCEGLIE AM, HOOFNAGLE JH. Elevations in serum alpha-fetoprotein levels in patients with chronic hepatitis B. Cancer 1989; 64: 2117-2120. http://dx.doi.org/10.1002/1097-014 2(19891115)64:10<2117::AID-CNCR2820641024>3.0.CO;2-7
12. LIEBMAN HA, FURIE BC, TONG MJ, BLANCHARD RA, LO KJ et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 1984; 310: 1427-1431. http://dx.doi.org/10.1056/NEJM198405313102204
13. BRUIX J, SHERMAN M, LLOVET JM, BEAUGRAND M, LENCIONI R et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430.
14. WHITING P, RUTJES AW, REITSMA JB, BOSSUYT PM, KLEIJNEN J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003; 3: 25. http://dx.doi.org/10.1186/1471-2288-3-25
15. WHITING P, HARBORD R, KLEIJNEN J. No role for quality scores in systematic reviews of diagnostic accuracy studies. BMC Med Res Methodol 2005; 5: 19. http://dx.doi. org/10.1186/1471-2288-5-19
16. REITSMA JB, GLAS AS, RUTJES AW, SCHOLTEN RJ, BOSSUYT PM et al. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005; 58: 982-990. http://dx.doi. org/10.1016/j.jclinepi.2005.02.022
17. HIGGINS JP, THOMPSON SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558. http://dx.doi. org/10.1002/sim.1186
18. HARBORD RM, WHITING P, STERNE JA, EGGER M, DEEKS JJ et al. An empirical comparison of methods for meta-analysis of diagnostic accuracy showed hierarchical models are necessary. J Clin Epidemiol 2008; 61: 1095-1103. http://dx.doi.org/10.1016/j.jclinepi.2007.09.013
19. DEEKS JJ, MACASKILL P, IRWIG L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 2005; 58: 882-893. http://dx.doi.org/10.1016/j.jclinepi.2005.01.016
20. SEVERENS JL, SONKE G, LAHEIJ RJ, VERBEEK AL, DE VRIES ROBBE PF. Efficient diagnostic test sequence: applications of the probability-modifying plot. J Clin Epidemiol 2001; 54: 1228-1237. http://dx.doi.org/10.1016/S0895-4356(01)00391-2
21. FAGAN TJ. LETTER: Nomogram for Bayes theorem. N Engl J Med 1975; 293: 257. http://dx.doi.org/10.1056/NEJM197507312930513
22. STENGEL D, BAUWENS K, SEHOULI J, EKKERNKAMP A, PORZSOLT F. A likelihood ratio approach to meta-analysis of diagnostic studies. J Med Screen 2003; 10: 47-51. http://dx.doi. org/10.1258/096914103321610806
23. BACHTIAR I, KHENG V, WIBOWO GA, GANI RA, HASAN I et al. Alpha-1-acid glycoprotein as potential biomarker for alpha-fetoprotein-low hepatocellular carcinoma. BMC Res Notes 2010; 3: 319.
24. BAEK YH, LEE JH, JANG JS, LEE SW, HAN JY et al. Diagnostic role and correlation with staging systems of PIVKA-II compared with AFP. Hepatogastroenterology 2009; 56: 763-767.
25. BEALE G, CHATTOPADHYAY D, GRAY J, STEWART S, HUDSON M et al. AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in nonalcoholic and alcoholic fatty liver disease. BMC Cancer 2008; 8: 200. http://dx.doi.org/10.1186/1471-2407-8-200
26. CUI R, HE J, ZHANG F, WANG B, DING H et al. Diagnostic value of protein induced by vitamin K absence (PIVKAII) and hepatoma-specific band of serum gamma-glutamyl transferase (GGTII) as hepatocellular carcinoma markers complementary to alpha-fetoprotein. Br J Cancer 2003; 88: 1878-1882. http://dx.doi.org/10.1038/sj.bjc.6601018
27. DURAZO FA, BLATT LM, COREY WG, LIN JH, HAN S et al. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 2008; 23: 1541-1548. http://dx.doi.org/10.1111/j.1440-1746.2008.05395.x
28. KUROMATSU R, TANAKA M, SHIMAUCHI Y, SHIMADA M, TANIKAWA K et al. Usefulness of ED036 kit for measuring serum PIVKA-II levels in small hepatocellular carcinoma. J Gastroenterol 1997; 32: 507-512. http://dx.doi.org/10.1007/BF02934091
29. LOK AS, STERLING RK, EVERHART JE, WRIGHT EC, HOEFS JC et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2010; 138: 493-502. http://dx.doi.org/10.1053/j.gastro.2009.10.031
30. MARRERO JA, FENG Z, WANG Y, NGUYEN MH, BEFELER AS et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009; 137: 110-118.
31. MARRERO JA, SU GL, WEI W, EMICK D, CONJEEVARAM HS et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology 2003; 37: 1114-1121. http://dx.doi.org/10.1053/jhep.2003.50195
32. MITA Y, AOYAGI Y, YANAGI M, SUDA T, SUZUKI Y et al. The usefulness of determining des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma. Cancer 1998; 82: 1643-1648. http://dx.doi.org/10.1002/(SICI)1097-0142(19980501)82:9<1643::AID-CNCR8>3.0.CO;2-B
33. NAKAMURA S, NOUSO K, SAKAGUCHI K, ITO YM, OHASHI Y et al. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol 2006; 101: 2038-2043. http://dx.doi. org/10.1111/j.1572-0241.2006.00681.x
34. NOMURA F, ISHIJIMA M, KUWA K, TANAKA N, NAKAI T et al. Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma. Am J Gastroenterol 1999; 94: 650-654. http://dx.doi.org/10.1111/j.1572-0241.1999.00930.x
35. OKUDA H, NAKANISHI T, TAKATSU K, SAITO A, HAYASHI N et al. Measurement of serum levels of desgamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity. Cancer 1999; 85: 812-818. http://dx.doi. org/10.1002/(SICI)1097-0142(19990215)85:4<812::AIDCNCR8> 3.0.CO;2-O
36. SASSA T, KUMADA T, NAKANO S, UEMATSU T. Clinical utility of simultaneous measurement of serum high-sensitivity des-gamma-carboxy prothrombin and Lens culinaris agglutinin A-reactive alpha-fetoprotein in patients with small hepatocellular carcinoma. Eur J Gastroenterol Hepatol 1999; 11: 1387-1392. http://dx.doi.org/10.1097/00042737-199912000-00008
37. SHARMA B, SRINIVASAN R, CHAWLA YK, KAPIL S, SAINI N et al. Clinical utility of prothrombin induced by vitamin K absence in the detection of hepatocellular carcinoma in Indian population. Hepatol Int 2010; 4: 569-576. http://dx.doi. org/10.1007/s12072-010-9186-2
38. STERLING RK, JEFFERS L, GORDON F, VENOOK AP, REDDY KR et al. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clin Gastroenterol Hepatol 2009; 7: 104-113. http://dx.doi.org/10.1016/j.cgh.2008.08.041
39. VOLK ML, HERNANDEZ JC, SU GL, LOK AS, MARRERO JA. Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer Biomark 2007; 3: 79-87.
40. WANG CS, LIN CL, LEE HC, CHEN KY, CHIANG MF et al. Usefulness of serum des-gamma-carboxy prothrombin in detection of hepatocellular carcinoma. World J Gastroenterol 2005; 11: 6115-6119.
41. YOON YJ, HAN KH, KIM DO Y. Role of serum prothrombin induced by vitamin K absence or antagonist-II in the early detection of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Scand J Gastroenterol 2009; 44: 861-866. http://dx.doi.org/10.1080/00365520902903034
42. XH C, RT C, BE W, JD J, FK Z et al. The Diagnostic Value of the Des-gamma-Carboxy Prothrombic Caused by the Vitamin K Absence in the Hepatic Carcinoma. Chinese Journal of Clinical Gastroenterology 2002: 156-159.
43. SCHUPPAN D, AFDHAL NH. Liver cirrhosis. Lancet 2008; 371: 838-851. http://dx.doi.org/10.1016/S0140-6736(08)60383-9
44. JAESCHKE R, GUYATT GH, SACKETT DL. Users' guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. JAMA 1994; 271: 703-707. http://dx.doi. org/10.1001/jama.271.9.703
45. COLLI A, FRAQUELLI M, CASAZZA G, MASSIRONI S, COLUCCI A et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol 2006; 101: 513-523. http://dx.doi.org/10.1111/j.1572-0241.2006.00467.x